Drug Profile
Research programme: Nanobodies - Ablynx/Sanofi
Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Ablynx; Genzyme Corporation
- Developer Ablynx; Sanofi
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for preclinical development in Multiple-sclerosis in Belgium (Parenteral)
- 28 Jun 2019 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (Parenteral)
- 19 Jun 2018 Ablynx has been acquired by Sanofi